^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FL-101

    i
    Other names: FL-101
    Associations

    News

    Trials
    Company:
    Leap Therap
    Drug class:
    IL-1β inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    FL- 101 Study in Non-Metastatic MIBC (clinicaltrials.gov)
    P1, N=0, Withdrawn, Flame Biosciences | Not yet recruiting --> Withdrawn
    Trial withdrawal
    |
    CRP (C-reactive protein)
    |
    FL-101
    almost2years
    Phase 0 Study of FL-101 in Non-Metastatic MIBC (clinicaltrials.gov)
    P1, N=5, Not yet recruiting, Flame Biosciences
    New P1 trial
    |
    CRP (C-reactive protein)
    |
    FL-101
    over2years
    FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Flame Biosciences | N=90 --> 0 | Trial completion date: Feb 2023 --> Dec 2021 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2022 --> Dec 2021
    Clinical • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • FL-101
    over2years
    FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Flame Biosciences | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • FL-101
    almost3years
    Phase 2 study of FL-101 in non-small cell lung cancer (clinicaltrialsregister.eu)
    P2, N=90, Ongoing, Flame Biosciences
    New P2 trial
    |
    IL6 (Interleukin 6) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • FL-101
    almost3years
    FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Flame Biosciences | N=180 --> 90 | Trial completion date: Apr 2025 --> Feb 2023 | Initiation date: Apr 2021 --> Jul 2021 | Trial primary completion date: Nov 2023 --> Oct 2022
    Clinical • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • FL-101
    3years
    FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Flame Biosciences
    Clinical • New P2 trial
    |
    CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • FL-101